The overall goal of this program has been to understand the genetic basis of human leukemias, and to develop novel therapeutic approaches based on these insights. During the past 9 years of the program, we have made major strides in this regard, including characterization of mutant FLT3 alleles in human leukemias in cell culture and murine models of leukemia, developing and testing small molecule tyrosine kinase inhibitors as therapeutic agents, and bringing these small molecule inhibitors forward into Phase I and Phase II clinical trials. During the next proposed 5-year study period we will build on these successes, and expand our efforts into new therapeutic venues based on recent findings and discoveries among members of the Program Project. In Project 1, Dr. Griffin will focus on improving the efficacy of FLT3 inhibitors by using """"""""combination targeted therapy"""""""", by evaluating the mechanisms of clinical resistance to FLT3 inhibitors, and initiating efforts to develop small molecule tyrosine kinase inhibitors of JAK2V617F as therapeutic agents in the myeloproliferative diseases. Dr. Gilliland will focus in Project 2, on understanding the relative contributions of FLT3-ITD and FLT3 activation loop mutations to the pathogenesis of myeloid and lymphoid leukemias, respectively, using knock-in alleles of these FLT3 mutants. He will focus continued effort on understanding cooperation of these alleles with other leukemia associated alleles, such as PML-RARa, C/EBPa, MLL and AML1-ETO, and in developing accurate murine models of JAK2V617F MPD for testing inhibitors developed in Project 1. In Project 3, Dr. Tenen will continue efforts to better understand the contributions of mutant hematopoietic transcription factors in pathogenesis of leukemia, including PML-RARa, C/EBPa, and PU.1. Dr. Armstrong is a new addition to the Program, and will study the role of MLL fusion genes in leukemogenesis, alone and in cooperation with mutations of C/EBPa based on recent data suggesting that these alleles cooperate, and will further characterize leukemia stem cells in murine models of MLL-AF4 and MLL-AF9 mediated leukemias. Dr. Stone will continue to lead the clinical translational component of this Program in Project 5, and will initially focus on continued development of FLT3 inhibitors in """"""""up-front"""""""" trials with induction chemotherapy to treat AML, and to implement novel therapies as they are developed and validated in the other projects, including, for example, JAK2 inhibitors for treatment of MPD. These Projects will each be supported by the Tissue Banking and Flow Cytometry Core B run by Dr. Jerome Ritz, and by close interactions with the Biostatistical Core C run by Dr. Donna Neuberg in all aspects of clinical trial design in human and murine model systems. Collectively, the Program will build on previous strengths and a demonstrated track record of success in the pipeline of developing novel therapies that begins with target gene discovery, development of preclinical models of transformation, development and testing of molecularly targeted therapies, and clinical implementation in Phase I and Phase II trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA066996-13
Application #
7882409
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (O1))
Program Officer
Merritt, William D
Project Start
1997-04-25
Project End
2013-03-30
Budget Start
2010-04-15
Budget End
2011-03-31
Support Year
13
Fiscal Year
2010
Total Cost
$2,408,966
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Weinberg, Olga K; Gibson, Christopher J; Blonquist, Traci M et al. (2018) Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities. Haematologica 103:626-633
Hoshii, Takayuki; Cifani, Paolo; Feng, Zhaohui et al. (2018) A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response. Cell 172:1007-1021.e17
Gooptu, Mahasweta; Kim, Haesook T; Chen, Yi-Bin et al. (2018) Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. Biol Blood Marrow Transplant 24:2216-2223
Gutierrez-Martinez, Paula; Hogdal, Leah; Nagai, Manavi et al. (2018) Diminished apoptotic priming and ATM signalling confer a survival advantage onto aged haematopoietic stem cells in response to DNA damage. Nat Cell Biol 20:413-421
Nabet, Behnam; Roberts, Justin M; Buckley, Dennis L et al. (2018) The dTAG system for immediate and target-specific protein degradation. Nat Chem Biol 14:431-441
Kleppe, Maria; Koche, Richard; Zou, Lihua et al. (2018) Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell 33:29-43.e7
List, Alan; Ebert, Benjamin L; Fenaux, Pierre (2018) A decade of progress in myelodysplastic syndrome with chromosome 5q deletion. Leukemia 32:1493-1499
Ebert, Benjamin L; Krönke, Jan (2018) Inhibition of Casein Kinase 1 Alpha in Acute Myeloid Leukemia. N Engl J Med 379:1873-1874
Sellar, Rob S; Jaiswal, Siddhartha; Ebert, Benjamin L (2018) Predicting progression to AML. Nat Med 24:904-906
Hshieh, Tammy T; Jung, Wooram F; Grande, Laura J et al. (2018) Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers. JAMA Oncol 4:686-693

Showing the most recent 10 out of 376 publications